JP Morgan Maintains Overweight on Cytokinetics, Raises Price Target to $75

Benzinga Newsdesk www.benzinga.com Positive 73.2%

Neg 0% Neu 0% Pos 73.2%

JP Morgan analyst Tessa Romero maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises the price target from $74 to $75.